{"id":"vilazodone","brandName":"Viibryd","genericName":"vilazodone","companyId":"abbvie","companyName":"AbbVie","phase":"marketed","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":1,"mechanism":{"target":"5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 4, 5-hydroxytryptamine receptor 7"},"administration":{"route":"Oral"},"safety":{"boxedWarnings":["WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1)]. Vilazodone hydrochloride tablets are not approved for use in pediatric patients [see Use in Specific Populations (8.4)]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. • Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients (5.1). • Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors (5.1). • Vilazodone hydrochloride tablets are not approved for use in pediatric patients (8.4)."],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"1111 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"809 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"808 reports"},{"date":"","signal":"ANXIETY","source":"FDA FAERS","actionTaken":"662 reports"},{"date":"","signal":"INSOMNIA","source":"FDA FAERS","actionTaken":"634 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"610 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"565 reports"},{"date":"","signal":"DEPRESSION","source":"FDA FAERS","actionTaken":"522 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"508 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"490 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Insomnia","drugRate":"","severity":"common","organSystem":""},{"effect":"Sedation","drugRate":"","severity":"frequent","organSystem":""},{"effect":"Tremor","drugRate":"","severity":"frequent","organSystem":""},{"effect":"Dry eye","drugRate":"","severity":"infrequent","organSystem":""},{"effect":"Vision blurred","drugRate":"","severity":"infrequent","organSystem":""},{"effect":"Hyperhidrosis","drugRate":"","severity":"infrequent","organSystem":""},{"effect":"Night sweats","drugRate":"","severity":"infrequent","organSystem":""},{"effect":"Ventricular extrasystoles","drugRate":"","severity":"infrequent","organSystem":""},{"effect":"Migraine","drugRate":"","severity":"infrequent","organSystem":""},{"effect":"Panic attack","drugRate":"","severity":"infrequent","organSystem":""},{"effect":"Cataracts","drugRate":"","severity":"rare","organSystem":""}],"contraindications":["Bipolar disorder","Blood coagulation disorder","Hyponatremia","Neuroleptic malignant syndrome","Seizure disorder","Serotonin syndrome","Suicidal","Suicidal thoughts","Syndrome of inappropriate vasopressin secretion"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":["NCT01999920","NCT01742832","NCT01828515","NCT01573598","NCT01878292","NCT06591091","NCT01473394","NCT00644358","NCT05422612","NCT01473381","NCT00290914","NCT05948579","NCT01715519","NCT02015546","NCT00683592","NCT01680900","NCT02372799","NCT01766401","NCT00285376","NCT01838876","NCT02028026","NCT02893371","NCT01574183","NCT02097147","NCT01629966","NCT03321526","NCT01856127","NCT01916824","NCT02436239","NCT01712321","NCT01715805","NCT01608295","NCT01844115","NCT01469377"],"indications":{"approved":[{"name":"Major depressive disorder","diseaseId":"major-depressive-disorder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT01999920","phase":"Phase 4","title":"Vilazodone for Separation Anxiety Disorder","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","isPivotal":false,"enrollment":24,"indication":"Separation Anxiety Disorder","completionDate":"2017-12-30"},{"nctId":"NCT01742832","phase":"Phase 2","title":"Double-Blind Switch Study of Vilazodone in the Treatment of Major Depressive Disorder Following Partial Response to or Inability to Tolerate a Generic SSRI","status":"COMPLETED","sponsor":"University of Chicago","isPivotal":false,"enrollment":79,"indication":"Major Depressive Disorder","completionDate":"2016-03"},{"nctId":"NCT01828515","phase":"Phase 2","title":"Vilazodone for Corticosteroid-Induced Memory Impairment","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","isPivotal":false,"enrollment":24,"indication":"Memory Impairment","completionDate":"2014-04"},{"nctId":"NCT01573598","phase":"Phase 4","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":false,"enrollment":1219,"indication":"Major Depressive Disorder","completionDate":"2015-01"},{"nctId":"NCT01878292","phase":"Phase 3","title":"A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":true,"enrollment":529,"indication":"Major Depressive Disorder","completionDate":"2016-10-05"},{"nctId":"NCT06591091","phase":"Phase 2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","isPivotal":false,"enrollment":80,"indication":"Depression","completionDate":"2026-03"},{"nctId":"NCT01473394","phase":"Phase 4","title":"A Double-blind, Placebo-controlled, Fixed-dose Study of Vilazodone in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":false,"enrollment":518,"indication":"Major Depressive Disorder","completionDate":"2013-02"},{"nctId":"NCT00644358","phase":"Phase 3","title":"A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":true,"enrollment":616,"indication":"Major Depressive Disorder","completionDate":"2009-05-31"},{"nctId":"NCT05422612","phase":"Phase 2","title":"A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventi","status":"RECRUITING","sponsor":"Global Coalition for Adaptive Research","isPivotal":false,"enrollment":800,"indication":"Post Traumatic Stress Disorder","completionDate":"2026-09"},{"nctId":"NCT01473381","phase":"Phase 4","title":"A Double-blind, Placebo- and Active-controlled, Fixed-dose Study of Vilazodone in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":false,"enrollment":1162,"indication":"Major Depressive Disorder","completionDate":"2013-06"},{"nctId":"NCT00290914","phase":"Phase 2","title":"","status":"COMPLETED","sponsor":"Pharmacology Research Institute","isPivotal":false,"enrollment":0,"indication":"Major Depressive Disorder","completionDate":""},{"nctId":"NCT05948579","phase":"Phase 2","title":"A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventi","status":"NOT_YET_RECRUITING","sponsor":"Global Coalition for Adaptive Research","isPivotal":false,"enrollment":200,"indication":"Post Traumatic Stress Disorder","completionDate":"2026-09"},{"nctId":"NCT01715519","phase":"Phase 4","title":"A Double-blind, Placebo-controlled Randomized Trial of Vilazodone in the Treatment of Posttraumatic Stress Disorder","status":"COMPLETED","sponsor":"Southern California Institute for Research and Education","isPivotal":false,"enrollment":59,"indication":"PTSD, Depression","completionDate":"2015-12"},{"nctId":"NCT02015546","phase":"Phase 3","title":"A Randomized, Double-Blind, 8-week Comparing Safety and Tolerability of Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhib","status":"COMPLETED","sponsor":"Duke University","isPivotal":true,"enrollment":70,"indication":"Major Depressive Disorder (MDD)","completionDate":"2013-12"},{"nctId":"NCT00683592","phase":"Phase 3","title":"A Randomized, Double-blind, Placebo Controlled Study Assessing the Efficacy and Safety of Vilazodone 40 mg qd and Evaluating Genetic Biomarkers Associated With Treatment Response in Patients With Majo","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":true,"enrollment":481,"indication":"Major Depressive Disorder","completionDate":"2009-03"},{"nctId":"NCT01680900","phase":"NA","title":"Vilazodone for Menopausal Hot Flashes: A Proof in Principle Study","status":"COMPLETED","sponsor":"University of Pennsylvania","isPivotal":false,"enrollment":36,"indication":"Hot Flushes","completionDate":"2013-08"},{"nctId":"NCT02372799","phase":"Phase 3","title":"A Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":true,"enrollment":473,"indication":"Major Depressive Disorder","completionDate":"2018-09-11"},{"nctId":"NCT01766401","phase":"Phase 3","title":"A Double-Blind, Placebo-Controlled, Flexible-Dose Study of Vilazadone in Patients With Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":true,"enrollment":402,"indication":"Generalized Anxiety Disorder","completionDate":"2014-01-29"},{"nctId":"NCT00285376","phase":"Phase 3","title":"A Randomized, Double-Blind, Placebo Controlled Study Assessing the Efficacy and Safety of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Genaissance Pharmaceuticals","isPivotal":true,"enrollment":410,"indication":"Depressive Disorder, Major","completionDate":"2007-05"},{"nctId":"NCT01838876","phase":"Phase 3","title":"A Phase 3, Long-term, Open-label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":true,"enrollment":442,"indication":"Major Depressive Disorder","completionDate":"2015-07-27"},{"nctId":"NCT02028026","phase":"Phase 4","title":"The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","isPivotal":false,"enrollment":0,"indication":"Major Depressive Disorder, Anxiety","completionDate":"2015-04"},{"nctId":"NCT02893371","phase":"N/A","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","isPivotal":false,"enrollment":1037352,"indication":"Bipolar Disorder","completionDate":"2019-06-30"},{"nctId":"NCT01574183","phase":"Phase 2","title":"Vilazodone Treatment for Marijuana Dependence","status":"COMPLETED","sponsor":"Medical University of South Carolina","isPivotal":false,"enrollment":76,"indication":"Marijuana Dependence","completionDate":"2016-02"},{"nctId":"NCT02097147","phase":"Phase 1","title":"A Multi-Center, Randomized, Double-Blind, Parallel-Group Study Evaluating The Sexual Functioning of Healthy Adults After Receiving Multiple-Dose Regimens of Vilazodone, Paroxetine, or Placebo","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":false,"enrollment":202,"indication":"Healthy","completionDate":"2014-11"},{"nctId":"NCT01629966","phase":"Phase 3","title":"A Double-blind, Placebo-Controlled Fixed-Dose Study of Vilazodone in Patients With Generalized Anxiety Disorder.","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":true,"enrollment":680,"indication":"Generalized Anxiety Disorder","completionDate":"2014-03-31"},{"nctId":"NCT03321526","phase":"Phase 2","title":"A 6-Month, Multicenter, Double-Blind, Randomized, Flexible-Dose, Parallel-Group Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","isPivotal":false,"enrollment":107,"indication":"Depressive Disorder, Major","completionDate":"2019-06-27"},{"nctId":"NCT01856127","phase":"Phase 4","title":"A Randomized, Double-Blind, Active Controlled Clinical Trial of Switching to Vilazodone for Antidepressant-Associated Sexual Dysfunction","status":"TERMINATED","sponsor":"Thomas Jefferson University","isPivotal":false,"enrollment":4,"indication":"Sexual Dysfunction, Major Depressive Disorder","completionDate":"2016-06"},{"nctId":"NCT01916824","phase":"Phase 4","title":"Effects of Treatment on Decision-making in Major Depression","status":"COMPLETED","sponsor":"Emory University","isPivotal":false,"enrollment":53,"indication":"Major Depressive Disorder, Healthy Controls","completionDate":"2015-12"},{"nctId":"NCT02436239","phase":"Phase 3","title":"An Open-label Long-term Safety Study of Vilazodone in Pediatric Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":true,"enrollment":330,"indication":"Major Depressive Disorder","completionDate":"2018-07-23"},{"nctId":"NCT01712321","phase":"NA","title":"Vilazodone in the Treatment of Social Anxiety Disorder: A Double Blind Study","status":"UNKNOWN","sponsor":"The Medical Research Network","isPivotal":false,"enrollment":30,"indication":"Social Anxiety Disorder","completionDate":"2014-04"},{"nctId":"NCT01715805","phase":"Phase 3","title":"A Phase 3, Double-Blind, Placebo-Controlled Study of Cariprazine as Adjunctive Therapy in Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":true,"enrollment":1022,"indication":"Major Depressive Disorder","completionDate":"2016-06-24"},{"nctId":"NCT01608295","phase":"Phase 4","title":"A Pilot Study of Double-blind Comparison of Vilazodone to Paroxetine in Geriatric Depression","status":"COMPLETED","sponsor":"University of California, Los Angeles","isPivotal":false,"enrollment":65,"indication":"Major Depressive Disorder","completionDate":"2015-09"},{"nctId":"NCT01844115","phase":"Phase 3","title":"A Double-Blind, Placebo-Controlled, Flexible-Dose Study of Vilazodone in Patients With Generalized Anxiety Disorder.","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":true,"enrollment":415,"indication":"Generalized Anxiety Disorder","completionDate":"2014-03-31"},{"nctId":"NCT01469377","phase":"Phase 2","title":"A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy in Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":false,"enrollment":819,"indication":"Major Depressive Disorder","completionDate":"2013-12-12"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$1.3448/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$491","description":"VILAZODONE HCL 10 MG TABLET","retrievedDate":"2026-04-07"}],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-04-07T00:00:00.000Z","mah":"ABBVIE","brand_name_local":null,"application_number":"NDA022567"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-06-07T00:00:00.000Z","mah":"ACCORD HLTHCARE","brand_name_local":null,"application_number":"ANDA208209"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-01-03T00:00:00.000Z","mah":"ALEMBIC","brand_name_local":null,"application_number":"ANDA208202"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-01-03T00:00:00.000Z","mah":"INVAGEN PHARMS","brand_name_local":null,"application_number":"ANDA208200"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-01-14T00:00:00.000Z","mah":"TEVA PHARMS USA","brand_name_local":null,"application_number":"ANDA208212"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=vilazodone","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:31:03.229084+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:31:10.214042+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:31:02.338355+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=vilazodone","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:31:10.545575+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:30:59.323327+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1)]. Vilazodone hydrochloride tablets are not approved for use in pediatric patients [see Use in Specific Populations (8.4)]. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS ","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:30:59.323369+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:31:11.984847+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Serotonin 1a (5-HT1a) receptor partial agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:31:11.572873+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1615374/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:31:11.236906+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA208202","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:30:59.323377+00:00"}},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:31:14.830625+00:00","fieldsConflicting":0,"overallConfidence":0.95},"crossReferences":{"chemblId":"CHEMBL1615374"},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}